The rise of continuous monitoring
2024
A CGM becomes available without a prescription
FDA Clears First Over-the-Counter Continuous Glucose Monitor
U.S. Food & Drug AdministrationMar 5, 2024
Innovation at GlucoSense
It's time to rethink diabetes innovation.
The way diabetes care gets built hasn't kept up with the people living with it. We're changing that.
Scroll
The problem
Diabetes is lived minute by minute.
But specialized diabetes care is scarce. Most U.S. counties have no endocrinologist, and half of adults with diabetes still aren't reaching their goals. Most of the work falls on people, alone, between appointments.
Its innovation moves in years.
New diabetes technology can take years to go from an idea to the people who need it. Every one of those years is lived one reading at a time.
37M+Americans living with diabetes
~70%of U.S. counties have no endocrinologist
6 minA year with an endocrinologist, on average
1 in 2adults with diabetes aren't reaching their A1c goal
CDC · GoodRx Research, 2024 · NEJM, 2021
What's changed
Today's technology makes change possible.
CGM enters the standard of care
2025
ADA extends CGM to adults with type 2 who don't take insulin
Your Guide to the 2025 ADA Standards of Care
diaTribe2025
The advancement of AI and LLMs
78.6%
of the time, evaluators preferred the AI's answers to patients' questions
Study Finds ChatGPT Outperforms Physicians in High-Quality, Empathetic Answers to Patient Questions
UC San Diego · JAMA Internal MedicineApr 2023
Clinical adoption of wearables
29%
of U.S. adults already wear a device that tracks their health
Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US
JAMA Network Open · YaleJun 2023
So we're rethinking diabetes care at every step.
GlucoSense is bringing the tools and pace of frontier AI labs to diabetes care, so everyone can have support that's accessible and truly personalized.
Our initiatives
01 · Rethinking how we build
GlucoSense Labs
To deliver better solutions to patients, faster.
- Continuous dataReal-world glucose and lifestyle data, flowing in around the clock.
- Frontier researchPaired with the latest research to model what could work.
- Parallel iterationReal-world simulations validate many hypotheses at once, not one at a time.
- Rapid shippingThe best ones reach people fast. Then we do it again.
02 · Rethinking how we deliver care
GlucoSense Platform
To scale personalized support, affordably.
- Sensor-driven careThe continuous story between visits.
- Flagging risk in real timePatterns that need attention surface early, highlighting who needs support most.
- Scaling affordable outreachSupport reaches everyone, not just the next appointment.
- Highly personalized supportCare and education shaped by each person's real-life experience.
Live today · 50 states · 250K+ insights a month
03 · Rethinking how we dose
Rheos
To lift the burden of managing diabetes.
- Contextualized dataHeart rate, sleep, meals and movement, each read in context.
- One comprehensive streamBrought together into a single picture of the person.
- Identifying momentsThe moments that matter come into focus.
- Personalized adjustmentDesigned to adapt to how each person actually lives.
Rheos is in development · Not cleared or approved by the FDA
Intelligence from data to delivery.
GlucoSense
We're always looking for clinicians, researchers and partners who want to build what comes next in diabetes care.
CAUTION: Rheos is an investigational device, limited by Federal (or United States) law to investigational use. It has not been cleared or approved by the FDA and is not available for sale. On-screen moments are illustrative.